Loading…
The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis
Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of...
Saved in:
| Published in: | Medicine (Baltimore) 2021-10, Vol.100 (42), p.e27510-e27510 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3556-e5e37f387f7173c5839e6d834d56ece150cf45b25e50af0e4c0e90066dd298e43 |
| container_end_page | e27510 |
| container_issue | 42 |
| container_start_page | e27510 |
| container_title | Medicine (Baltimore) |
| container_volume | 100 |
| creator | Yang, Meiqi Liu, Weixin Deng, Qiuping Liang, Zeng Wang, Qin |
| description | Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of the skin system (e.g., psoriasis). Psoriasis is recognized as the most common skin lesion, capable of significantly affecting the quality of patients' life.
This study searched literatures published in English language with the qualifications on PubMed, Embase, Web of Science, Google, and Geenmedical databases. Over 2 co-authors assessed the quality of the articles and extracted the data independently. The data acquired were statistically analyzed with the statistical software of Revman and Stata.
The ADA Group achieved a higher incidence of psoriasis (odds ratio [OR] = 0.658, 95% confidence interval [CI] [0.471-0.919]); Females achieved a higher incidence of psoriasis than males (OR = 1.941, 95%CI [1.326-2.843], P |
| doi_str_mv | 10.1097/MD.0000000000027510 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8542134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34678884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3556-e5e37f387f7173c5839e6d834d56ece150cf45b25e50af0e4c0e90066dd298e43</originalsourceid><addsrcrecordid>eNpdkd1u1DAQhS0EokvLEyAhv0Ba_8YJF0hVSwGpFTftdeR1xhvTxF7Z3kb7ZjxeHRaWn7mxZjznOxodhN5Rck5Jqy7urs_Jn2JKUvICrajkdSXbWrxEqzKVlWqVOEFvUvpOCOWKidfohItaNU0jVujH_QDYeeN68AZwsHibQnQ6uYT1FPwGpyk8Qiyd7y9CxDbECeJx6rwd9TTpHOIer8MMI-5dAp0g4a3ODnxOOEfQGXo8uzzgvJsKxoOJYTGx2hRtoWe9Cd6l_AFf4rRPGQrUGRzhycG8uOMJsq601-O-CM_QK6vHBG9_vafo4ebT_dWX6vbb569Xl7eV4VLWFUjgyvJGWUUVN7LhLdR9w0UvazBAJTFWyDWTIIm2BIQh0BJS133P2gYEP0UfD9ztbj1Bb8pBUY_dNrpJx30XtOv-_fFu6DbhqWukYJQvAH4ALAenCPaopaRbguzurrv_gyyq93_bHjW_kysL4rAwhzGXJB7H3QyxG0CPefjJk6plFSOMUsIYqRZ0zZ8BXVKvgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis</title><source>LWW Online</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Yang, Meiqi ; Liu, Weixin ; Deng, Qiuping ; Liang, Zeng ; Wang, Qin</creator><creatorcontrib>Yang, Meiqi ; Liu, Weixin ; Deng, Qiuping ; Liang, Zeng ; Wang, Qin</creatorcontrib><description>Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of the skin system (e.g., psoriasis). Psoriasis is recognized as the most common skin lesion, capable of significantly affecting the quality of patients' life.
This study searched literatures published in English language with the qualifications on PubMed, Embase, Web of Science, Google, and Geenmedical databases. Over 2 co-authors assessed the quality of the articles and extracted the data independently. The data acquired were statistically analyzed with the statistical software of Revman and Stata.
The ADA Group achieved a higher incidence of psoriasis (odds ratio [OR] = 0.658, 95% confidence interval [CI] [0.471-0.919]); Females achieved a higher incidence of psoriasis than males (OR = 1.941, 95%CI [1.326-2.843], P < .05); Smoking up-regulated the incidence of psoriasis (OR = 1.679, 95%CI [1.237-2.279], P < .05); The interval of medication was over 1 year, and the interval of medication applying IFX was longer than that of the ADA Group; most cases could be relieved by using local hormone, phototherapy, or systemic hormone therapy under the strategy of biological agents.
The frequency of reported in IBD exceeds those of other autoimmune diseases, and the ADA treatment for IBD is safer than IFX. Psoriasis is more common in females than in males. Smoking refers to one of risk factors of psoriasis.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000027510</identifier><identifier>PMID: 34678884</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Adalimumab - therapeutic use ; Gastrointestinal Agents - administration & dosage ; Gastrointestinal Agents - adverse effects ; Gastrointestinal Agents - therapeutic use ; Humans ; Incidence ; Inflammatory Bowel Diseases - drug therapy ; Inflammatory Bowel Diseases - epidemiology ; Infliximab - therapeutic use ; Psoriasis - drug therapy ; Psoriasis - epidemiology ; Risk Factors ; Sex Distribution ; Smokers - statistics & numerical data ; Systematic Review and Meta-Analysis ; Tumor Necrosis Factor Inhibitors - administration & dosage ; Tumor Necrosis Factor Inhibitors - adverse effects ; Tumor Necrosis Factor Inhibitors - therapeutic use</subject><ispartof>Medicine (Baltimore), 2021-10, Vol.100 (42), p.e27510-e27510</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3556-e5e37f387f7173c5839e6d834d56ece150cf45b25e50af0e4c0e90066dd298e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542134/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542134/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34678884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Meiqi</creatorcontrib><creatorcontrib>Liu, Weixin</creatorcontrib><creatorcontrib>Deng, Qiuping</creatorcontrib><creatorcontrib>Liang, Zeng</creatorcontrib><creatorcontrib>Wang, Qin</creatorcontrib><title>The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of the skin system (e.g., psoriasis). Psoriasis is recognized as the most common skin lesion, capable of significantly affecting the quality of patients' life.
This study searched literatures published in English language with the qualifications on PubMed, Embase, Web of Science, Google, and Geenmedical databases. Over 2 co-authors assessed the quality of the articles and extracted the data independently. The data acquired were statistically analyzed with the statistical software of Revman and Stata.
The ADA Group achieved a higher incidence of psoriasis (odds ratio [OR] = 0.658, 95% confidence interval [CI] [0.471-0.919]); Females achieved a higher incidence of psoriasis than males (OR = 1.941, 95%CI [1.326-2.843], P < .05); Smoking up-regulated the incidence of psoriasis (OR = 1.679, 95%CI [1.237-2.279], P < .05); The interval of medication was over 1 year, and the interval of medication applying IFX was longer than that of the ADA Group; most cases could be relieved by using local hormone, phototherapy, or systemic hormone therapy under the strategy of biological agents.
The frequency of reported in IBD exceeds those of other autoimmune diseases, and the ADA treatment for IBD is safer than IFX. Psoriasis is more common in females than in males. Smoking refers to one of risk factors of psoriasis.</description><subject>Adalimumab - therapeutic use</subject><subject>Gastrointestinal Agents - administration & dosage</subject><subject>Gastrointestinal Agents - adverse effects</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Humans</subject><subject>Incidence</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Inflammatory Bowel Diseases - epidemiology</subject><subject>Infliximab - therapeutic use</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - epidemiology</subject><subject>Risk Factors</subject><subject>Sex Distribution</subject><subject>Smokers - statistics & numerical data</subject><subject>Systematic Review and Meta-Analysis</subject><subject>Tumor Necrosis Factor Inhibitors - administration & dosage</subject><subject>Tumor Necrosis Factor Inhibitors - adverse effects</subject><subject>Tumor Necrosis Factor Inhibitors - therapeutic use</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkd1u1DAQhS0EokvLEyAhv0Ba_8YJF0hVSwGpFTftdeR1xhvTxF7Z3kb7ZjxeHRaWn7mxZjznOxodhN5Rck5Jqy7urs_Jn2JKUvICrajkdSXbWrxEqzKVlWqVOEFvUvpOCOWKidfohItaNU0jVujH_QDYeeN68AZwsHibQnQ6uYT1FPwGpyk8Qiyd7y9CxDbECeJx6rwd9TTpHOIer8MMI-5dAp0g4a3ODnxOOEfQGXo8uzzgvJsKxoOJYTGx2hRtoWe9Cd6l_AFf4rRPGQrUGRzhycG8uOMJsq601-O-CM_QK6vHBG9_vafo4ebT_dWX6vbb569Xl7eV4VLWFUjgyvJGWUUVN7LhLdR9w0UvazBAJTFWyDWTIIm2BIQh0BJS133P2gYEP0UfD9ztbj1Bb8pBUY_dNrpJx30XtOv-_fFu6DbhqWukYJQvAH4ALAenCPaopaRbguzurrv_gyyq93_bHjW_kysL4rAwhzGXJB7H3QyxG0CPefjJk6plFSOMUsIYqRZ0zZ8BXVKvgQ</recordid><startdate>20211022</startdate><enddate>20211022</enddate><creator>Yang, Meiqi</creator><creator>Liu, Weixin</creator><creator>Deng, Qiuping</creator><creator>Liang, Zeng</creator><creator>Wang, Qin</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20211022</creationdate><title>The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis</title><author>Yang, Meiqi ; Liu, Weixin ; Deng, Qiuping ; Liang, Zeng ; Wang, Qin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3556-e5e37f387f7173c5839e6d834d56ece150cf45b25e50af0e4c0e90066dd298e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adalimumab - therapeutic use</topic><topic>Gastrointestinal Agents - administration & dosage</topic><topic>Gastrointestinal Agents - adverse effects</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Humans</topic><topic>Incidence</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Inflammatory Bowel Diseases - epidemiology</topic><topic>Infliximab - therapeutic use</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - epidemiology</topic><topic>Risk Factors</topic><topic>Sex Distribution</topic><topic>Smokers - statistics & numerical data</topic><topic>Systematic Review and Meta-Analysis</topic><topic>Tumor Necrosis Factor Inhibitors - administration & dosage</topic><topic>Tumor Necrosis Factor Inhibitors - adverse effects</topic><topic>Tumor Necrosis Factor Inhibitors - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Meiqi</creatorcontrib><creatorcontrib>Liu, Weixin</creatorcontrib><creatorcontrib>Deng, Qiuping</creatorcontrib><creatorcontrib>Liang, Zeng</creatorcontrib><creatorcontrib>Wang, Qin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Meiqi</au><au>Liu, Weixin</au><au>Deng, Qiuping</au><au>Liang, Zeng</au><au>Wang, Qin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2021-10-22</date><risdate>2021</risdate><volume>100</volume><issue>42</issue><spage>e27510</spage><epage>e27510</epage><pages>e27510-e27510</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of the skin system (e.g., psoriasis). Psoriasis is recognized as the most common skin lesion, capable of significantly affecting the quality of patients' life.
This study searched literatures published in English language with the qualifications on PubMed, Embase, Web of Science, Google, and Geenmedical databases. Over 2 co-authors assessed the quality of the articles and extracted the data independently. The data acquired were statistically analyzed with the statistical software of Revman and Stata.
The ADA Group achieved a higher incidence of psoriasis (odds ratio [OR] = 0.658, 95% confidence interval [CI] [0.471-0.919]); Females achieved a higher incidence of psoriasis than males (OR = 1.941, 95%CI [1.326-2.843], P < .05); Smoking up-regulated the incidence of psoriasis (OR = 1.679, 95%CI [1.237-2.279], P < .05); The interval of medication was over 1 year, and the interval of medication applying IFX was longer than that of the ADA Group; most cases could be relieved by using local hormone, phototherapy, or systemic hormone therapy under the strategy of biological agents.
The frequency of reported in IBD exceeds those of other autoimmune diseases, and the ADA treatment for IBD is safer than IFX. Psoriasis is more common in females than in males. Smoking refers to one of risk factors of psoriasis.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>34678884</pmid><doi>10.1097/MD.0000000000027510</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2021-10, Vol.100 (42), p.e27510-e27510 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8542134 |
| source | LWW Online; IngentaConnect Journals; PubMed Central |
| subjects | Adalimumab - therapeutic use Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - adverse effects Gastrointestinal Agents - therapeutic use Humans Incidence Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - epidemiology Infliximab - therapeutic use Psoriasis - drug therapy Psoriasis - epidemiology Risk Factors Sex Distribution Smokers - statistics & numerical data Systematic Review and Meta-Analysis Tumor Necrosis Factor Inhibitors - administration & dosage Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - therapeutic use |
| title | The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T15%3A50%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20incidence%20of%20psoriasis%20among%20smokers%20and/or%20former%20smokers%20inflammatory%20bowel%20diseases%20patients%20treated%20with%20tumor%20necrosis%20factor%20antagonist:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Yang,%20Meiqi&rft.date=2021-10-22&rft.volume=100&rft.issue=42&rft.spage=e27510&rft.epage=e27510&rft.pages=e27510-e27510&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000027510&rft_dat=%3Cpubmed_cross%3E34678884%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3556-e5e37f387f7173c5839e6d834d56ece150cf45b25e50af0e4c0e90066dd298e43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34678884&rfr_iscdi=true |